Predicting Cognitive Impairment in Parkinson's Disease
Author Information
Author(s): Mohammed Hajir, Yousif Mohamed Atif Mohamed, Elhassan Mohamed, Elhussein Yassein, Badawi Dina, Gabralla Sarra, Abdelrahman Nadir
Hypothesis
Can genetic and serological biomarkers predict cognitive impairment in Parkinson's disease?
Conclusion
The study found that several biomarkers are significantly associated with cognitive decline in Parkinson's disease and could help in patient management.
Supporting Evidence
- The study assessed 9 studies with 11 different biomarkers.
- Biomarkers like the APOE4 allele and serum high mobility group box-1 levels were found to be significantly associated with cognitive decline.
- Longitudinal studies are needed to validate these biomarkers.
Takeaway
Scientists looked at different markers in the blood and genes to see if they can tell if someone with Parkinson's might have trouble thinking. They found some markers that could help doctors know who might need extra help.
Methodology
A systematic review of studies focusing on serological and genetic biomarkers related to cognitive impairment in Parkinson's disease.
Limitations
Further investigation is needed to validate the biomarkers and understand their roles in cognitive impairment.
Participant Demographics
Elderly population with Parkinson's disease.
Statistical Information
P-Value
0.003
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website